

COCHAIRS:

Thomas F. Gajewski, University of Chicago, Chicago, IL

Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX

Jedd D. Wolchok, Weill Cornell Medicine, New York, NY

[R] – remote presentation

FRIDAY, OCTOBER 21

Registration

3:00 pm-8:00 pm | Grand Liberty Foyer

Welcome and Opening Keynote Lecture

6:30 pm-7:30 pm | Grand Liberty Ballroom

- | | |
|-----------|-------------------------------------------------------------------------------------------------------|
| 6:30-6:35 | Welcome and Introduction of Keynote Speaker
Thomas F. Gajewski, University of Chicago, Chicago, IL |
| 6:35-7:15 | Stromal evolution in inflammation and cancer
Shannon J. Turley, Genentech, South San Francisco, CA |
| 7:15-7:30 | Discussion / Q&A |

Opening Reception

7:30 pm-9:30 pm | Back Bay Ballroom

SATURDAY, OCTOBER 22

Breakfast


7:00 am-8:00 am | Grand Liberty Foyer

Plenary Session 1: Adoptive T Cell Therapy with a Focus on Challenges in Solid Tumors

8:00 am-9:25 am | Grand Liberty Ballroom

Session Chair: Thomas F. Gajewski, University of Chicago, Chicago, IL

- | | |
|-----------|------------------------------------------------------------------------------------------------------------------------------------|
| 8:00-8:25 | Engineering CAR T cells for enhanced efficacy and specificity
Robbie Majzner, Stanford University School Medicine, Stanford, CA |
| 8:25-8:35 | Discussion / Q&A |
| 8:35-9:00 | TCR-gene therapy targeting mutant KRAS
Eric Tran, Providence Cancer Institute, Portland, OR |
| 9:00-9:10 | Discussion / Q&A |
| 9:10-9:25 | Panel Discussion |



Break

9:25 am-9:45 am | Grand Liberty Foyer

Plenary Session 2: Next-Generation Checkpoints Beyond PD-1 and CTLA-4

9:45 am-11:45 am | Grand Liberty Ballroom

Session Chair: Roberta Zappasodi, Weill Cornell Medicine, New York, NY

- | | |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| 9:45-10:10 | Targeting the LAG-3 immune checkpoint in cancer
Evan J. Lipson, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD |
| 10:10-10:20 | Discussion / Q&A |
| 10:20-10:45 | Targeting the adenosine pathway to augment the immune response
Zev A. Wainberg, UCLA Medical Center, Santa Monica, CA |
| 10:45-10:55 | Discussion / Q&A |
| 10:55-11:20 | Modulating tumor metabolism to reprogram the immune microenvironment against cancer
Roberta Zappasodi |
| 11:20-11:30 | Discussion / Q&A |
| 11:30-11:45 | Panel Discussion |

Lunch on Own / Free Time


11:45 am-1:45 pm

Plenary Session 3: Spatial Analysis of the Tumor Microenvironment

1:45 pm-3:45 pm | Grand Liberty Ballroom

Session Chair: Roberta Zappasodi, Weill Cornell Medicine, New York, NY

- | | |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1:45-2:10 | The power of ONE: Immunology in the age of single cell genomics
Ido Amit, Weizmann Institute of Science, Rehovot, Israel |
| 2:10-2:20 | Discussion / Q&A |
| 2:20-2:45 | [R] - Cancer rearranges the rules in tissue building blocks. A new class of targets for therapy?
Garry P. Nolan, Stanford University School of Medicine, Stanford, CA |
| 2:45-2:55 | Discussion / Q&A |
| 2:55-3:20 | Integrating multi-omics to unlock insights into cancer immunotherapy against hepatocellular carcinoma
Won Jin Ho, Johns Hopkins University, Baltimore, MD |
| 3:20-3:30 | Discussion / Q&A |



3:30-3:45 Panel Discussion

Poster Session A / Reception

4:00 pm-6:30 pm | Back Bay Ballroom

SUNDAY, OCTOBER 23

Breakfast

7:00 am-8:00 am | Grand Liberty Foyer

Plenary Session 4: Computational Models/AI/Big Data

8:00 am-10:00 am | Grand Liberty Ballroom

Session Chair: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX

- | | |
|------------|-------------------------------------------------------------------------------------------------------------------------------|
| 8:00-8:25 | Systems biology modeling of tumor immunotherapy
Lance L. Munn, Massachusetts General Hospital, Charlestown, MA |
| 8:25-8:35 | Discussion / Q&A |
| 8:35-9:00 | Immune selection and predictability of cancer evolution
Marta Luksa, Icahn School of Medicine at Mount Sinai, New York, NY |
| 9:00-9:10 | Discussion / Q&A |
| 9:10-9:35 | What about cancer is “not self”?
Benjamin D. Greenbaum, Memorial Sloan Kettering Cancer Center, New York, NY |
| 9:35-9:45 | Discussion / Q&A |
| 9:45-10:00 | Panel Discussion |

Break


10:00 am-10:20 am | Grand Liberty Foyer

Plenary Session 5: Host Factors Regulating Efficacy and Resistance

10:20 am-12:20 pm | Grand Liberty Ballroom

Session Chair: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX

- | | |
|-------------|-------------------------------------------------------------------------------------------------------------------|
| 10:20-10:45 | Insights from translational research on response to cancer therapy
Jennifer A. Wargo |
| 10:45-10:55 | Discussion / Q&A |
| 10:55-11:20 | Elucidating the impact of the microbiome on CAR T cell therapy
Melody Smith, Stanford University, Stanford, CA |
| 11:20-11:30 | Discussion / Q&A |



- 11:30-11:55 An unexpected role for androgens in limiting cancer immunotherapy efficacy
Amy Moran, Oregon Health & Science University, Portland, OR
- 11:55-12:05 Discussion / Q&A
- 12:05-12:20 Panel Discussion

Lunch on Own / Free Time

12:20 pm-2:30 pm

Plenary Session 6: Myeloid Cells in the Tumor Microenvironment

2:30 pm-3:40 pm | Grand Liberty Ballroom

Session Chair: Thomas F. Gajewski, University of Chicago, Chicago, IL

- 2:30-2:55 The complexities of tumor associated macrophages and the key to effective
targeting for anti-cancer therapy
Jennifer L. Guerriero, Dana-Farber Cancer Institute, Boston, MA
- 2:55-3:05 Discussion / Q&A
- 3:05-3:30 Commensal microbiota and germline variants can regulate anti-tumor immunity
through myeloid cells
Thomas F. Gajewski
- 3:30-3:40 Discussion / Q&A

Keynote Lecture

3:40 pm-4:40 pm | Grand Liberty Ballroom

- 3:40-3:45 Introduction of Keynote Speaker
Amy Moran, Oregon Health & Science University, Portland, OR
- 3:45-4:25 Sex bias and cancer immunotherapy: Time has come
Zihai Li, The Ohio State University – Pelotonia Institute for Immuno-Oncology,
Columbus, OH
- 4:25-4:40 Discussion / Q&A


Poster Session B / Reception

5:00 pm-7:30 pm | Back Bay Ballroom

MONDAY, OCTOBER 24

Breakfast

7:00 am-8:00 am | Grand Liberty Foyer



Plenary Session 7: Mechanisms of IO Toxicity

8:00 am-10:00 am | Grand Liberty Ballroom

Session Chair: Ryan J. Sullivan, Massachusetts General Hospital, Boston, MA

- | | |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 8:00-8:25 | Checkpoint blockade–induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1/Tc1 cytokines
Robin Reschke, University of Chicago, Chicago, IL |
| 8:25-8:35 | Discussion / Q&A |
| 8:35-9:00 | ICI-associated myocarditis: Bench to bedside
Javid Moslehi, University of California, San Francisco, CA |
| 9:00-9:10 | Discussion / Q&A |
| 9:10-9:35 | Uncoupling anti-tumor immunity and auto-inflammatory toxicity from immune checkpoint inhibition
Ryan J. Sullivan |
| 9:35-9:45 | Discussion / Q&A |
| 9:45-10:00 | Panel Discussion |

Break


10:00 am-10:20 am | Grand Liberty Foyer

Plenary Session 8: Neoadjuvant IO

10:20 am-12:20 pm | Grand Liberty Ballroom

Session Chair: Matthew Galsky, Icahn School of Medicine at Mount Sinai, New York, NY

- | | |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10:20-10:45 | Personalization of neoadjuvant therapy in melanoma: A template for other tumors?
Christian Blank, Netherlands Cancer Institute, Amsterdam, Netherlands |
| 10:45-10:55 | Discussion / Q&A |
| 10:55-11:20 | The evolution of neoadjuvant immunotherapy in bladder cancer
Matthew Galsky, Icahn School of Medicine at Mount Sinai, New York, NY |
| 11:20-11:30 | Discussion / Q&A |
| 11:30-11:55 | [R] - From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 11:55-12:05 | Discussion / Q&A |
| 12:05-12:20 | Panel Discussion |



AACR Special Conference
**Tumor Immunology
and Immunotherapy**
October 21-24, 2022 | Boston, MA

AACR
American Association
for Cancer Research®

2206010E

Departure
12:20 pm